Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipatasertib and Pembrolizumab in First Line Recurrent or Metastatic Head and Neck Squamous Cell Cancer
NCT05172258Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jul 2022
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ipatasertib in squamous cell carcinoma of the head and neck (HNSCC) (2 arms), sponsored by National Cancer Institute. Primary endpoint: Progression-Free Survival. Started Jul 2022; status: active, not recruiting.
02
Drugs
ipatasertib
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT05172258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05172258.